» Our Priorities
Areas of Policy Research and Development
Here at GHPI, we’re tackling a diversity of policy initiatives in Washington, D.C. and around the world, as we educate public officials about the outstanding work currently being done by our Fellows. Here are a few examples of core priorities that we currently engage on behalf of our growing global coalition of public and private stakeholders, that guide and strengthen our work every step of the way:
- Connecting our Fellows to the new $1.8 billion annual NIH fund for Cures currently under congressional approval through the 21st Century Act, ensuring that these funds can be used to address the systemic and underlying causes of aging-related disease.
- Uniting a diverse community of public policy, private industry, and consumer group stakeholders behind the goals of the TAME/Metformin study.
- Promoting relevant attempts by key pharmaceutical industry players to follow in the footsteps of the TAME/Metformin study by initiating similar FDA-approved clinical trials
- Helping identify bottlenecks and the strategies for engaging them to promote the research, development and application of quality healthspan therapies, via consulting experts in the relevant fields, in all the stages, from research and translation to clinical application and distribution.
- Identifying possible facilitating mechanisms, processes, and legislations for the development of quality healthspan therapies and searching for ways to join, contribute to, and improve upon these mechanisms.
- Mapping agencies from which new funding can be used to support healthspan research and the possible procedural means to achieve these allocations (e.g. through specific types of legislation, parliamentary and governmental procedures, managerial decision, informal consensus, specific agencies, etc.)
- Suggesting criteria or even specific measures and markers for the efficacy and safety of quality healthspan substances and therapies, to derive from the current criteria and categories for therapies, biomarkers, and frailty indexes and devising new and improved criteria and methodologies.
- Suggesting regulatory statuses that can be utilized to advance quality healthspan treatments and cures.
- Listing desirable incentives and benefits that should be suggested, and the procedures for obtaining them for specific categories of all public and private stakeholders.